Manufacturer: Dragon Pharma
Pharmaceutical name: Mazdutide
Pack: 1 vial (10 mg)
Mazdutide is the first medication in its class, functioning as a dual glucagon-like peptide 1 receptor agonist (GLP-1RA) and glucagon receptor agonist. By stimulating both GLP1R and glucagon receptors, it aids in managing appetite, metabolism, and enhances glucose control. While its dual mechanism shows potential, further clinical trials are necessary.
GLP-1 receptors are prevalent in the pancreas's beta-cells, the brain, and various other tissues and play a critical role in regulating blood sugar levels by boosting insulin secretion, among other functions. GLP-1 receptor agonists (GLP-1RAs) are already commonly used to treat type 2 diabetes since they promote insulin production and release in a glucose-dependent manner, leading to weight reduction. These medications also slow gastric emptying, manage blood lipid levels, minimize fat accumulation, and possess neuroprotective, anti-infective, and cardiovascular protective properties.
By themselves, glucagon receptor agonists are not an optimal treatment choice as they elevate glucose production in the liver, but when combined with GLP-1RAs, they effectively decrease fat mass and enhance glucose tolerance.
Side effects:
Clinical trials have indicated that mazdutide is generally well tolerated, with mild side effects reported, including:
- upper respiratory tract infection
- diarrhea
- decreased appetite
- nausea
- urinary tract infection
- abdominal distension (bloating)
- vomiting.
Mazdutide is administered via a prefilled autoinjector, delivered subcutaneously (under the skin), typically in the abdominal area, on a weekly basis.